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Abstract
Biomonitoring of food and environmental matrices is critical for the rapid and sensitive
diagnosis, treatment, and prevention of diseases caused by toxins. The U.S. Centers for
Disease Control and Prevention (CDC) has noted that toxins from bacteria, fungi, algae,
and plants present an ongoing public health threat, especially since some of these toxins
could compromise security of the food supply. Botulinum neurotoxins (BoNTs), pro‐
duced by Clostridium spp., are among those bacterial toxins that pose life-threatening
danger to humans. BoNTs inhibit the release of acetylcholine at peripheral cholinergic
nerve terminals and cause flaccid paralysis. BoNTs are grouped in seven serotypes and
many subtypes within these groups. Rapid and accurate identification of these toxins in
contaminated food as well as in environmental matrices can help direct treatment. Here‐
in, we discuss current methods to detect BoNTs with a focus on how these technologies
have been used to identify toxins in various food and environmental matrices. We also
discuss the emergence of new serotypes and subtypes of BoNTs and the increasing num‐
ber of cases of botulism in wildlife. Finally, we consider how environmental changes im‐
pact food safety for humans and present new challenges for detection technology.
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1. Introduction
The U.S. Centers for Disease Control (CDC) have summarized the risks that biological toxins
pose to human health [1]. Bacteria, fungi, parasites, and plants all produce toxins in the
environment that can impact food safety. Furthermore, changes in the environment have
caused emergence of new problems associated with toxins. One example is the production of
toxins by Clostridium botulinum. This pathogen, which is a gram-positive, anaerobic spore-
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forming bacterium, produces botulinum neurotoxins (BoNTs). Humans are susceptible to the
effects of these poisons, which are among the most toxic molecules known [1]. The parenteral
lethal dosage for humans is 0.1–1 ng/kg, and the oral dose is 1 µg/kg. A single gram of BoNT
released into the environment and subsequently inhaled could kill more than one million
people [2, 3]. BoNTs exert their biological effects by blocking acetylcholine release by neurons.
To date, BoNTs have been divided into seven serotypes, denoted as A through G, of which A,
B, E, and F are known to be toxic to humans [4–6]. However, all of the botulinum serotypes
are possibly toxic to people. In addition to the principal serotypes, at least 40 additional
subtypes have been described based on differences in both primary peptide sequence and
three-dimensional structure [4–6]. In this discussion, we review the basic biology of BoNTs
and current methods to detect these molecules in biological and environmental matrices.
C. botulinum isolates are categorized into different groups [5, 6]. Members of Group I are
referred to as “proteolytic” and produce toxin types A, B, or F. They are widely distributed in
the environment and often found in various raw foods. BoNTs can cause symptoms at levels
as low as 5 ng. Although the onset of symptoms typically takes 12–36 hours, the time course
depends on the amount of toxin ingested [2, 3]. It can take much longer for symptoms to
manifest. Initial symptoms include diarrhea and vomiting followed by neurological effects
that include blurred vision, weakness, and difficulty in swallowing, talking, and breathing.
Unless diagnosed early, mortality rates can be as high as 40% [1–4]. Timely response and
current treatments have reduced mortality to less than 10%. The most common foods involved
in outbreaks are improperly preserved meat or fish products, but a range of other foods have
been implicated, such as cheeses (including vegetables preserved in oil and cheese). Because
botulinum toxins are not heat stable, they can be inactivated at cooking temperatures.
Strains in Group II are classified as “non-proteolytic” [5, 6]. These C. botulinum strains
synthesize neurotoxin B, E, or F. These bacteria can grow at temperatures <3°C are ubiquitous
in the environment. Moreover, one can find Type E strains in aquatic habitats [1–4]. It is not
known whether these strains can synthesize neurotoxins in refrigerated processed foods
without visible spoilage. The endospores of strains in this group are not as resistant to heat as
those strains in Group I. Neurotoxins synthesized by strains in Group II toxins have shown to
be less potent than those of Group I; at least 0.1 µg of neurotoxin is required to cause symptoms
of botulism. However, their other biological properties are similar. Foods involved in out‐
breaks of Group II botulism include cold-smoked fish and other preserved fish products.
Group III botulinum produces toxins of serotype C or D and is associated with avian and non-
human mammalian botulism [5, 6]. Whole genome sequencing analysis indicates that strains
of physiological group III are probably more related to Clostridium haemolyticum and Clostri‐
dium novyi than to C. botulinum serotypes belonging to Groups I and II. Group IV is rare and
has not been well characterized. However, it does synthesize neurotoxin serotype G.
Bacteriophages contain the neurotoxin genes of C. botulinum serotypes C and D [5, 6]. The
BoNT prophage replicates in the bacterium as a large plasmid, and strains containing the phage
can become toxigenic via either type C or type D phages. The distinction between types C and
D is not clear because chimeric sequences have been isolated from the environment. These
toxin genes have been identified in avian isolates. They contain sections from both BoNT/C
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and BoNT/D genes and are referred to as type C/D [5, 6]. The chimeric toxin is more pathogenic
to avians than either serotype C or D individually. In C. botulinum serotypes C and D, there is
a small amount of a binary toxin, denoted as the C2 toxin. The genes encoding the C2 toxin
have been localized to a plasmid. Structurally and functionally, the C2 toxin contains a
translocation domain and an ADP-ribosylating domain that has been shown to target cellular
actin. The occurrence of other chimeric botulinum toxin genes has yet to be determined [5, 6].
At the amino acid sequence level, BoNT serotypes can differ from one other by 34–64% [5, 6].
Significant genetic variation within each serotype has also been observed. In fact, 32 toxin
subtypes with amino acid sequence differences of 2.6–32% have been identified thus far, and
more will likely be identified in the future [5, 6]. This serotype and subtype diversity confound
direct antibody and molecular-based assay designs. It is rare that one probe can bind to all
serotypes. In C. botulinum, the neurotoxins are first synthesized as a large holotoxin (approx‐
imately 150 kDa). They are then processed by a trypsin-like protease in C. botulinum yielding
two polypeptides (one approximately 100 kDa and the other approximately 50 kDa) that are
still bound by a single disulfide [2, 3]. The neurotoxin structure mimics other known A–B
dimeric toxins found in other bacterial pathogens. The ~100 kDa fragment is called the heavy
chain (HC) and aids the binding of the neurotoxin to host cell receptors and its translocation
from vesicles to the cytoplasm [2, 3]. The ~50 kDa fragment, called the light chain (LC), contains
the enzymatically active domain of the neurotoxin. Recombinantly, expressed LC is routinely
used for activity-based neurotoxin assays. Antibodies specific for the HC and LC are used for
immunoassays for detecting neurotoxins as well as for neutralization.
2. Important factors to consider when developing toxin detection assays
The development of a robust assay for the detection of any pathogen or biological product of
a pathogen (such as a toxin) requires consideration of several factors: sensitivity, specificity,
matrix effects, and biological activity [8–10]. Each of these factors is briefly discussed below in
the context of assay methods for C. botulinum toxins.
3. The mouse bioassay
In the laboratory, a rodent bioassay is considered the “gold standard” method for detecting
BoNTs [8–10]. Despite much effort to replace the use of animals, it is still the most sensitive
and reliable assay to model all aspects of BoNT intoxication: binding, translocation, enzymatic
activity, and pathology. Alternatives to the mouse bioassay have been developed (discussed
below) with shorter assay times and equal or greater sensitivity.
The mouse assay quantitatively determines the amount of BoNT required to kill all mice in
a test  group. This measurement is  expressed as a minimal lethal dose (MLD). Although
protocols may vary, mice are usually injected intraperitoneally with 0.5 mL of BoNT sample
in a dilution series and then monitored over several days for signs of intoxication and death
Technologies for Detecting Botulinum Neurotoxins in Biological and Environmental Matrices
http://dx.doi.org/10.5772/63064
127
[11, 12]. If enough sample is available for an assay, the specific neurotoxin can be identi‐
fied using neutralization with antibodies specific to each of the neurotoxin serotypes (A–
G). The toxin serotype is therefore revealed based on which antibody confers protection from
death. The mouse bioassay is highly sensitive and useful for detection of different neurotox‐
ins in different matrices. However, despite its versatility, the mouse assay has limitations that
include:  long assay times  and the  use  of  animals  requiring specialized animal  facilities,
substantial costs, trained staff, and consideration of ethical issues, especially when death is
used as an endpoint. There is also substantial variation in results observed among different
research laboratories [8–12].
Alternative “refined” animal assays that do not use death as an endpoint, such as the mouse
phrenic nerve hemi-diaphragm assay, have been evaluated [13, 14]. Despite being more
sensitive and rapid compared to the use of whole animals, these assays usually require the use
of specific equipment and personnel with specialized training. Furthermore, these alternative
animal assays are not feasible with larger samples and those containing a complex matrix.
However, a recent study described an in vivo assay using a toe-spread reflex model. This
method was used to detect neurotoxins in simple buffer solutions, samples containing serum,
and milk [15]. This new assay provides results more quickly than standard mouse bioassays.
Whether these results can be translated into a user-friendly, deployable kit has yet to be
determined.
4. DNA and other nucleic acid–based methods
Numerous nucleic acid methods have been developed for detecting clostridial DNA in biological
and environmental matrices. The polymerase chain reaction (PCR) to identify the presence of
C. botulinum DNA was originally used to detect the presence of bacterial spores in samples [16].
The method is capable of detecting the presence of as few as 100 spores per reaction mixture for
serotypes A, E, and F and only 10 spores per reaction mixture for serotype B.
Multiplex PCR methods have also been developed to analyze unknowns for a battery of
different targets such as different pathogens and/or associated gene products of these patho‐
gens. Multiplexed assays employ different combinations or sets of PCR primers, each one
specific for a gene of interest, to amplify multiple targets in one PCR tube. One such multiplex
method could possibly discriminate among BoNT serotypes A, B, E, and F. As previously
described, Peck et al. [16] developed a culture enrichment method that, when coupled with
multiplex PCR, could identify strains of C. botulinum that were non-proteolytic (such as BoNT
serotypes B, E, and F). This method was robust and rapid enough for use with food samples
contaminated with C. botulinum.
Real-time PCR (RT-PCR) or quantitative PCR (qPCR) is also useful in studies of gene expres‐
sion, specifically differential expression of genes under various environmental conditions or
comparative studies of different organisms. For detection of clostridial DNA, RT-PCR methods
examine expression of the NTNH (non-toxic, non-hemagglutinin) and numerous other genes
in C. botulinum serotypes A, B, E, and F [18]. Pentaplex methods have been developed to
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simultaneously identify and discriminate among larger numbers of different serotypes, using
a wider array of different genes [19]. This technology may prove to be efficient and cost-
effective.
The GeneDisc Cycler is an apparatus to perform RT-PCR applications using the GeneDisc
system. The GeneDisc is a disposable plastic reaction tray that is the size of a compact disc.
This method has been designed for simultaneously testing for the BoNT/A, BoNT/B, BoNT/E,
and BoNT/F genes. In 2011, Fach et al. evaluated the GeneDisc Cycler equipment with
neurotoxin-producing clostridia and non-BoNT-producing bacteria isolated from various
clinical, food, and environmental samples [20]. Results obtained using this “macroarray” were
also compared to the mouse bioassay. The toxin genes were detected in all clostridial serotypes
A, B, E, and F as well as in toxigenic Clostridium baratii Type F and toxigenic Clostridium
butyricum Type E. No cross-reactivity was observed with bacteria not toxigenic to humans as
well as C. botulinum Types C, D, and G. An evaluation of the GeneDisc array was performed
in four European laboratories with BoNT-producing clostridia and 10 different samples that
included food matrices and clinical isolates [20]. Results demonstrated the technology to be
specific and reliable in the identification of C. botulinum cells containing genes encoding
neurotoxins A, B, E, and F. Furthermore, contaminated food and fecal samples were success‐
fully tested. This assay is highly sensitive, capable of detecting as low as 5–50 genome copies
in each PCR assay. The GeneDisc Cycler can also be used for monitoring neurotoxin-producing
clostridia in food samples, clinical samples, and environmental matrices. A similar study was
carried out examining a focused microarray for detection of genes-encoding BoNTs [21].
Recently, Kolesnikov et al. [22] described a new method called “proteolytic PCR” in which
PCR is used to assay the proteolytic activity of botulinum toxin. This technology starts with
DNA–protein complexes attached to a solid phase. Proteolytic cleavage releases DNA into
solution. The DNA can then serve as a template for PCR. This study described its use to detect
botulinum toxin and tetanus toxin proteolytic activity [22].
5. Immunological and antibody-based assays
Enzyme-linked immunosorbent assay (ELISA) is a common assay used to detect BoNTs. This
method utilizes anti-BoNT capture and detector antibodies arranged in a “sandwich” format.
The detection formats are most commonly luminescent- or colorimetric-based. Prior genera‐
tions of BoNT immunoassays were approximately 10 times less sensitive than the mouse
bioassay described in the previous section. Although not as sensitive, ELISA methods are
relatively fast, inexpensive, and simple to perform. They are also less subject to inhibitory
matrix effects. An amplified ELISA for detecting toxins in food matrices has also been described
[23]. Toxins for serotypes A, B, E, and F could be detected in liquids, solid food, and semisolid
food. Assay performance was evaluated in a range of food matrices, such as broccoli, orange
juice, bottled water, cola soft drinks, vanilla extract, oregano, potato salad, apple juice, meats,
and dairy foods. The assay sensitivity varied for each botulinum serotype. The tests readily
detected 2 ng/mL of serotypes A, B, E, and F in various foods tested. Recently, traditionally
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formatted, very sensitive sandwich ELISAs used high affinity mAbs against BoNT/A and
BoNT/B to detect BoNT/A as low as 5 and 25 pg/mL in buffer and in a milk matrix, respectively;
and BoNT/B at 100 fg/mL and 39 pg/mL in buffer and milk matrix, respectively [24–26].
These mAbs were used in an electrochemiluminesence (ECL) immunosorbent assay using the
Sector 2400 Imager (Meso Scale Discovery [MSD], Rockville, MD, USA) instrument [27, 28].
Detection sensitivities for BoNT/A in this system were similar to traditional ELISAs in buffer
but were markedly improved in liquid food matrices because of the reduced background
signal. The higher sensitivity and reduced time required for these new immunosorbent
methods make them potential alternatives to the mouse bioassay. Sharma et al. recently
developed another ECL assay for simultaneous detection of several biothreat agents (including
clostridial neurotoxins) in milk products, with limit of detection (LOD) of 40 pg/mL for BoNT/
A complex [28]. The ECL assay was also successfully applied to screen C. botulinum serotype
A outbreak strains. The study also showed that this sensitive ECL assay is rapid (it can be
completed in less than 6 hours). The ECL assay also has potential for using as an in vitro
screening method, complementing or replacing other immunoassays.
Cheng and Stanker [27] evaluated the performance of antitoxin mAbs using the same electro‐
chemiluminescence immunoassay platform (Sector 2400 Imager, MSD). The ELISA and ECL
methods were observed to be more sensitive than the mouse bioassay. In fact, the ECL assay
was able to outperform ELISA in terms of detection sensitivity—including food matrices
spiked with BoNT/A and in some food matrices spiked with BoNT/B. The ELISA and ECL
methods are fast and simple alternatives to the mouse bioassay and can be used for detecting
BoNTs in food matrices and serum samples.
One example of mAb development using a recombinant immunogen was the work of Liu et
al. [29], who expressed the recombinant H(C) subunit of BoNT type A (rAH(C)). Two out of
56 mAbs were selected to establish a highly sensitive sandwich chemiluminescence enzyme
immunoassay (CLEIA) with LOD for both rAH(C) and BoNT/A of 0.45 pg/mL. This CLEIA
can be used to detect BoNT/A in matrices, such as milk and beef extract. This method is 20–
40-fold more sensitive than the mouse bioassay and takes only 3 hours to complete, making it
a useful method to detect and quantify BoNT/A.
The multiplex technology discussed above to detect nucleic acid has also been applied to the
development of methods to analyze multiple epitopes on a single antigen and multiple targets
in a single sample. This approach uses multiple mAbs as well as polyclonal antibodies to
reduce false-positive and false-negative results. A commercialized system, Luminex xMAP
technology, utilizes microsphere beads conjugated with antibodies. It employs paramagnetic
beads instead of non-magnetic polystyrene beads and is very useful for the analysis of food
matrices. The antibody-bead complexes detect multiple epitopes in a single sample. This
technology was used to detect abrin, ricin, BoNTs, and staphylococcal enterotoxins in spiked
food samples [30].
Zhang et al. [31] developed ELISA-based protein antibody microarrays to simultaneously
detect six serotypes of BoNTs. Using numerous different food and other matrices, the micro‐
array is capable of detecting BoNT serotypes A through F. Using engineered, high-affinity
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antibodies, these serotypes were detected to similar levels in various matrices and were
comparable to detection in buffer.
Accurate and sensitive detection of contaminated food and other biological samples in the
environment is critical. Brunt et al. [32] have developed an affinity column-based assay for
detecting neurotoxin in food matrices—specifically serotypes A, B, E, and F. The detection
limit for BoNT/A was reported as 0.5 ng, which is two-fold more sensitive than lateral flow
methods (also see Section 6) [32]. For serotypes B, E, and F, the minimum detection limit ranged
from 5 to 50 ng. Although not as sensitive as ELISA or mouse bioassay, rapid immunochro‐
matographic methods generally require only 15–30 minutes to complete. They do not require
enrichment steps and are amenable to use in the field.
Koh et al. have presented a new technology called SpinDx [33]. This method utilizes a
centrifugal microfluidic platform to detect BoNTs based on a sedimentation immunoassay. A
reagent mixture is prepared, consisting of capture beads conjugated with target-specific
antibodies and fluorescent detection antibodies. The reagents are mixed with the sample and
forced through a channel containing dense medium, a process that washes the sample and
removes interfering substances. The beads that collect at the end of the channel are queried to
determine the amount of antigen bound. SpinDx was used to quantify BoNTs with sensitivity
that surpassed the mouse assay.
6. Lateral flow methods
The development of lateral flow methods for detecting toxins has also led to the commercial
availability of numerous kits for sensitive and rapid testing. Lateral flow methods employ
capture antibodies that are “printed” on nitrocellulose membranes in a process akin to inkjet
printing technology. Detection antibodies are labeled with visible materials, such as colloidal
gold or colored latex beads. The sample is added to a reagent pad containing labeled toxin-
binding detection antibodies and is wicked across the membrane. Toxin is retained by the
capture antibody, which also concentrates the labeled detection antibody. A positive reaction
is revealed as a colorimetric change and is presented as a line on the device. In general, lateral
flow methods are qualitative and simply determine the presence or absence of neurotoxin.
Sharma et al. [34] compared several commercial lateral flow devices for their capacities to
detect toxin in food samples. They were able to detect BoNT/A and BoNT/B as low as 10
ng/mL and BoNT/E at 20 ng/mL in various liquids, such as milk, soft drinks, and fruit juices.
Ching et al. [35] used the same mAbs described in the ELISA section above [24–26] in lateral
flow devices to achieve sensitivities of 0.5 and 1 ng/mL for BoNT/A in buffer and milk,
respectively. Although simple lateral flow tests have lower sensitivities compared to other
methods, they produce rapid results and are most useful for the rapid screening of samples
suspected of frequent contamination at relatively high level of BoNT. They have many
applications and are ideal for field use by non-technical personnel. Self-contained and not
necessarily requiring additional reagents or equipment, they can be easily interpreted in the
field.
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An innovative approach for toxin detection has recently been developed that combines
antibodies with the amplification power of PCR, immuno-PCR (I-PCR) [36]. In I-PCR, template
DNA is conjugated to the antibody, replacing a secondary antibody conjugated to the detection
enzyme. Upon binding of toxin by the antibody, the presence of toxin is revealed using PCR.
Chao et al. [36] described an I-PCR method for detection of BoNT/A with femtogram (10−15 g)
sensitivity. These investigators compared competitive and sandwich ELISA to the I-PCR
method. The I-PCR method was 103–105 times more sensitive with LODs for the ELISA
methods of about 50 fg. The use of I-PCR for highly sensitive detection of BoNT in food matrices
or other biological and environmental backgrounds has yet to be reported (as of late 2015).
7. Mass spectrometry-based methods to detect toxins
Mass spectrometry (MS) has been used as a method to dissect components of botulinum toxin
complexes [37–39]. The MS-based method, called ENDOPEP-MS, uses antibodies to concen‐
trate and extract BoNT from test samples [38]. The concentrated toxins are then subjected to
an endopeptidase activity–based assay to generate target cleavage products. Finally, MS is
used to identify these products. This approach has been successful in identifying BoNT
serotypes A, B, E, and F in various food and clinical matrices with greater sensitivity than the
mouse bioassay.
Morineaux et al. [40] recently described a MS method that employs immunocapture enrich‐
ment by antibodies specific for BoNT/A-L chains. The enriched analyte is then analyzed by
liquid chromatography–tandem mass spectrometry (LC–MS/MS) on a triple quadrupole mass
spectrometer (QqQ) in multiple reaction monitoring (MRM) mode. Peptides from BoNT LC
specific to the subtypes BoNT/A1–A3 and BoNT/A5–A8 could be identified. BoNT/A subtypes
were correctly identified in culture supernatants, water, and orange juice samples with a LOD
of 20–150 mouse lethal doses (LDs), but there was a lower sensitivity in serum samples.
Kalb et al. [41] have described the development of a quantitative enzymatic method for the
detection of four BoNT serotypes using matrix-assisted laser desorption/ionization—time of
flight (MALDI-TOF) MS. Factors that might affect the linearity and dynamic range for
detection of BoNT cleavage products were carefully examined, including the concentration of
the substrate and internal standard, the length of time for the cleavage reaction, and the
components present in the reaction solution. Longer incubation time produced more sensitive
results but was not capable of determining higher toxin concentrations, whereas a shorter
incubation time was less sensitive. To address these limitations, a novel two-step analysis was
developed [41]. By combining the results from a two-stage quantification, four or five orders
of magnitude in dynamic range are observed for detection of BoNT serotypes A, B, D, and F.
To minimize the number of cleavage reactions and analytical samples, the assay can be
multiplexed using mixtures of different neurotoxin substrates. Numerous different research
groups (including Kalb et al. [42], Björnstad et al. [43], and Hines et al. [37]) have used MS to
dissect the components of the BoNT/G complex, revealing BoNT/G as well as other toxin
protein components, namely NTNH, HA-17, HA-33, and HA-70. Overall, the use of MS can
provide rapid and definitive results.
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8. Enzymatic assays to detect toxins
Rapidly distinguishing between the presence of active versus inactive toxin is critical for
effective medical intervention in toxicoses. As BoNTs are zinc metalloproteases, knowledge
of the human targets for these enzymes has enabled development of enzyme-substrate assays.
Activity assays have been developed using a wide variety of detection systems. Toxin samples
can be treated with recombinant versions of host–target substrates (such as SNAP-25), and the
cleavage products can be detected using immunoblotting. Alternatively, fluorogenic peptide
substrates emit a signal when cleaved. One such system uses a peptide (“SNAPtide”) with
reverse-phase HPLC and a fluorescence detector to detect as low as 5 pg/mL of BoNT/A in
skim milk [45]. Other peptide substrates (VAMPtide and SYNTAXtide) have been used for
detection of their cognate BoNTs [46]. The levels of substrate cleavage correlate well with toxin
activity.
9. Cell-based assays
Cell-based assays measure BoNT receptor binding, translocation, and enzymatic activity and
can be in vitro alternatives to the mouse bioassay. Several neuronal and non-neuronal cell lines
have been analyzed for use in neurotoxin assays. These include the following: BE(2)-M17 cells,
chick embryo neuronal cells, neuroblastoma cells, and rat spinal cord cells [47–50]. In general,
the endpoint of cell-based assays for BoNT/A is the proteolytic cleavage of its intracellular
substrate, the vesicle-trafficking SNARE protein called SNAP-25. Recently, Hubbard et al. [51,
52] described the functional analysis of numerous different biological neurotoxins, including
BoNTs, in networked cultures of stem cell–derived central nervous system neurons. The
investigators demonstrate synaptic activity in cultured neurons of humans and rodents,
suggesting that these could serve as comparable methods to animal studies. Hong et al. [53]
have also developed a similar assay using a motor neuron-like continuous cell line. Pathe-
Neuschäfer-Rube et al. [54] developed a N-terminal tagged luciferase-expressing neuronal cell
line. Luciferase is released from these transfected cells during depolarization, which is blocked
by botulinum toxin. Cell-based methods may prove to be equally sensitive, or better, than
animal studies and may provide a new alternative for in vivo experiments. For example, for
the first time, the U.S. Food and Drug Administration approved a cell-based assay developed
by the biotechnology company Allergan, Inc. (Irvine, CA, USA) for its use as an alternative to
the mouse bioassay. However, the details of the Allergan assay have not been published.
10. New antibody and biosensor technologies
Diamant et al. [55] have used an interesting approach for generating antibodies that have
higher specificity against serotypes A, B, and E, and possess neutralizing capabilities. Mice
were immunized with a “trivalent mixture” of recombinant fragments of neurotoxins A, B,
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and E. The method generated numerous different monoclonal antibodies against each
serotype. Most of the monoclonal antibodies had higher ELISA titers compared to polyclonal
antibodies and had specificities with five orders of magnitude greater specificity. These
antibodies also protected against neurotoxin dosages of 10–50 LD50. They also observed a
neutralizing synergy when serotype-specific monoclonal antibodies were combined into an
oligoclonal mixture.
Detection methods can also utilize highly sensitive antibodies to enrich or enhance sample
preparation as well as amplify the signal. For example, an assay with a large immunosorbent
surface area (ALISSA) [56, 57] utilizes an antibody to concentrate the neurotoxin onto the
surface of a large bead. The “captured” toxin molecules are then used in an enzyme assay.
Using food matrices, the LOD for ALISSA was observed as low as 50 fg/mL. This is far more
sensitive than the mouse bioassay, immunoassay, or enzyme assay and suggests that it may
be useful for detecting food contamination. Marconi et al. [58, 59] have also described the use
of surface plasmon resonance (SPR) to examine synaptic vesicle capture by antibodies against
BoNT substrates, such as SNAP25 and VAMP2. SPR could be used with cultured neurons in
96-well plates incubated with either BoNT/A or BoNT/B and may be an alternative to animal
studies. Further development of label-free and optical biosensors for detecting botulinum toxin
[61, 62] will provide additional technologies with possible impact on food safety.
11. Challenges for botulinum neurotoxin detection: new serotypes in the
environment
Kull et al. [62] described the isolation of a novel C. botulinum strain associated with an outbreak
of botulism in Germany. Genotyping of the isolate and subsequent comparison of its neuro‐
toxin gene sequences with database sequences revealed it as a novel BoNT/A serotype. This
novel isolate has been called BoNT/A8, and its neurotoxin gene is located within a HA-orfX+
locus. Unique among all other BoNT/A subtypes known so far, an arginine insertion was
identified in the HC domain of the HC. Both the full-length neurotoxin and the recombinant
LC of BoNT/A8 had lower endopeptidase activity compared to BoNT/A1. Reduced ganglioside
binding and lower enzymatic activity may both contribute to lower biological activity of BoNT/
A8 as determined using the phrenic nerve hemi-diaphragm assay. Nevertheless, the novel
BoNT/A8 subtype caused severe botulism in a 63-year-old male. These findings reiterate that
subtyping of BoNT is highly relevant to food safety, epidemiology, and clinical diagnostic and
therapeutic practices. Hill et al. [63] carried out a detailed genetic analysis of bont genes and
confirmed their location on chromosomes, phagemids, and plasmids, as well as variations
among different genes. Close examination of sequences confirmed that horizontal gene
transfer, site-specific insertions, and recombination events have contributed to the observed
variation among different neurotoxins. Understanding the details of toxin gene sequences,
protein sequences, and their function can pave the way for the development of novel thera‐
peutics and tailor-made antitoxins. Ongoing development of diagnostics for new and emerg‐
ing toxins is critical to food safety and human health.
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12. Botulinum neurotoxin detection in the environment: role of climate
change and algal blooms in avian botulism and the challenges of
environmental matrices
Increased global temperature has been associated with increased algal blooms. The role of
these algal blooms in disease is unclear. However, recently, a connection between algal blooms
and botulism has been explored. Avian botulism is a disease that often occurs on a yearly cycle
and results from the ingestion of neurotoxins by birds. This disease has become increasingly
common in the U.S. Great Lakes [64], as have blooms of the green alga Cladophora, which can
serve as a potential habitat for C. botulinum. The interactions between Cladophora and C.
botulinum are unclear due to the complex food web associated with this disease. Investigators
in several recently published studies [64–66] reported a high number of botulism cases in
shoreline birds in Lake Michigan. This increased incidence was correlated with increasingly
large accumulations of Cladophora in the water. Sadowsky et al. [65] examined algal mats that
were collected from Lakes Michigan, Ontario, and Erie in 2011–2012 and then compared them
with algal populations in sand and water. They found that 96% of Cladophora mats collected
from the shorelines in 2012 contained C. botulinum Type E. Among the algae samples contain‐
ing detectable C. botulinum, the large number of detected C. botulinum type E cells indicated
that Cladophora mats are principal sources of this pathogen. Mouse toxin and antitoxin
bioassays further confirmed the toxin in collected samples as serotype E. Further examination
of Cladophora-associated C. botulinum may lead to a model system to study algal–clostridial
interactions and result in lower bird mortality.
In a follow-up study using PCR, Sadowsky et al. [66] reported that algae mats from different
shores of the Great Lakes contained the serotype E gene. Also, C. botulinum was found to be
present in amounts of up to 15,000 cells per gram of dried algae, based on quantitation of gene
copies encoding serotype E. Moreover, genes for serotypes A and B, which are associated with
human diseases, were detected in several of the algal samples. Using mouse toxin assays and
subsequent neutralization assays, it was confirmed that Cladophora-associated C. botulinum was
serotype E. One might consider that with increased incidence of extreme drought and other
environmental changes, algal blooms may happen more often in water-restricted areas, and
C. botulinum growth may pose a threat to humans if toxin is produced in algal mats. Developing
sensitive detection methods for toxins within algal matrices is urgent, as is monitoring other
matrices that could provide an environment for botulinum toxin production. The increased
avian botulism associated with increased algal blooms highlights the need to develop new
technologies for detection of toxin in the environment, or a re-evaluation of current methods
and their use in environmental matrices.
Vidal et al. [67] examined numerous environmental factors that influence the prevalence of
the unusual mosaic BoNT serotype C/D. Between 1978 and 2008, 13 avian botulism outbreaks
were observed, killing 20,000 birds. A significant association was found between the number
of dead birds recorded in each botulism outbreak and the mean temperature in July (with
average temperatures being higher than 26°C). The presence of C. botulinum type C/D in
wetland sediments was detected by qPCR. Furthermore, low concentrations of chloride ions
Technologies for Detecting Botulinum Neurotoxins in Biological and Environmental Matrices
http://dx.doi.org/10.5772/63064
135
and high organic matter content were correlated with the presence of C. botulinum. The
digestive tracts of dead birds found during botulism outbreaks were also analyzed; C.
botulinum was present in almost 40% of the studied samples. Recently, Le Maréchal et al. [68]
examined livers from dead birds suspected of having botulism and showed that this organ can
serve as a reliable matrix for RT-PCR confirmation of disease. This finding may provide
wildlife investigators with a faster method to confirm avian deaths due to botulism.
The presence of C. botulinum was detected in aquatic invertebrates and flesh-eating inverte‐
brates collected around bird carcasses. Moreover, the presence of C. botulinum bacteria in the
adult fly stage of some invertebrates raises the question of whether flies can transport C.
botulinum from one carcass to another. The same investigators examined whether adult
blowflies could play a significant role in botulism outbreaks by carrying C. botulinum between
carcasses. A field experiment and subsequent laboratory tests determined that blowflies could
transport C. botulinum Type C/D between carcasses [69]. These results confirm that adult flesh-
eating flies could play a role in avian botulism outbreaks. An environmental monitoring
protocol for botulinum-carrying flies has not yet been established. It is a matter for future
research to determine whether these or other insects could serve as mechanical vectors for
botulinum isolates that pose greater threats to humans than the avian isolates.
Probably, one of the greatest challenges is determining which environmental matrices should
be collected and analyzed, and which ones would provide the most definitive information
about potential threats to humans and animals. For instance, Anza et al. [70] examined the role
of eutrophication and avian botulism outbreaks in wetlands receiving effluents from urban
wastewater treatment plants. Numerous different avian pathogens, including clostridial
pathogens, were present in wastewater and could pose a threat to birds living in wastewater
wetlands. Methods to detect BoNTs in environmental matrices could be adapted from previous
studies of food and clinical samples or may require new technologies. Future studies in this
area are clearly warranted.
13. Future technologies to detect botulinum neurotoxins
The discussion herein has presented a general overview of methods currently being used to
detect BoNTs. Many current methods to detect BoNTs in food and environmental matrices
have been adapted from the clinical laboratory. New possibilities to consider, to name a few,
could exploit the tools of nanotechnology, mHealth, and the use of mobile devices, the
capability of miniaturization for even more sensitive and rapid detection of BoNTs. The
application and practical use of these technologies might be valuable advancements to current
methods to detect BoNTs.
14. Conclusions and recommendations
To maintain a safe food supply and to detect toxins in an ever-changing environment, an
ongoing, concerted effort in assay development and validation is essential for human health
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and safety. Some areas for investigators to consider include the development of new antibodies
and binding molecules specific to BoNT serotype F as well as new hybrid serotypes. The impact
of different types of neurotoxin accessory proteins on the detection of BoNTs should also be
examined. Furthermore, the impact of food processing conditions on the stability and bioa‐
vailability BoNTs is an area in need of further study. The development of new bioassays based
on non-mammalian systems and cell cultures should also be supported as well as the ad‐
vancement of new portable and field-deployable testing methods, including those based on
miniaturization of current bench top instruments. These are only a few recommendations, but
their development and use should help to further ensure food safety and animal and human
health.
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